This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares

OrbiMed Advisors sold 143,304 shares of Sionna Therapeutics in Q4, an estimated $5.43 million based on quarterly average prices. The disclosure likely reflects a portfolio trim or rebalancing by OrbiMed and is routine; it is unlikely to materially move Sionna shares absent further developments.

Analysis

OrbiMed Advisors sold 143,304 shares of Sionna Therapeutics in Q4, an estimated $5.43 million based on quarterly average prices. The disclosure likely reflects a portfolio trim or rebalancing by OrbiMed and is routine; it is unlikely to materially move Sionna shares absent further developments.